Quantitative analysis for Immuneering Corporation (IMRX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (35.0) (grade D). Gem alpha score: 36.0. 32 signals analyzed (27 differentiated alt-data).
IMRX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $5.34 | $5.16 | $5.25 |
| 2026-05-11 | $5.46 | $5.20 | $5.20 |
| 2026-05-21 | $5.27 | $4.90 | $5.22 |
| 2026-06-03 | $4.60 | $4.23 | $4.55 |
| 2026-06-15 | $4.33 | $4.13 | $4.19 |
| 2026-06-26 | $4.78 | $4.49 | $4.76 |
| 2026-07-09 | $5.70 | $5.34 | $5.36 |
| 2026-07-21 | $4.51 | $4.27 | $4.46 |
| 2026-07-31 | $4.28 | $4.06 | $4.13 |
| 2026-08-12 | $5.10 | $4.73 | $5.07 |
| 2026-08-24 | $5.35 | $5.13 | $5.18 |
| 2026-09-03 | $5.10 | $4.93 | $5.04 |
How Immuneering Corporation stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | $184M | — |
| IFRX | InflaRx N.V. | $176M | 38.0 |
| ALMR | Alamar Biosciences, Inc. | $189M | — |
| ORMP | Oramed Pharmaceuticals Inc. | $173M | — |
View all Health Care stocks by valuation and signals →
Immuneering Corporation (IMRX) scores Sell (35.0), and the composite conceals a 94-point disagreement between its dimensions. It is strongest on competitive moat at 94 and analyst consensus at 82, and weakest on technicals at 15 and AI Alpha (gem) at 0. A stock can carry competitive moat that high while AI Alpha (gem) sits at 0; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 94 |
| analyst consensus | 82 |
| ML forecast | 69 |
| technicals | 15 |
| AI Alpha (gem) | 0 |
StoQuant analyzes 32 signals (27 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Immuneering Corporation (IMRX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/IMRX"><img src="https://stoquant.com/badge/IMRX.svg" alt="Immuneering Corporation (IMRX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.